nipah
viru
niv
continu
caus
outbreak
fatal
human
enceph
due
spillov
bat
reservoir
determin
singl
dose
replicationdefect
vesicular
stomat
viru
vsv
base
vaccin
vector
express
either
niv
fusion
f
attach
g
glycoprotein
protect
hamster
time
ld
niv
challeng
highli
effect
singledos
protect
coupl
enhanc
safeti
profil
make
candid
ideal
potenti
use
livestock
human
order
evalu
protect
efficaci
vaccin
lethal
niv
challeng
anim
model
mimic
niv
diseas
test
vaccin
syrian
golden
hamster
debuyssch
et
al
guillaum
et
al
rockx
et
al
wong
et
al
obtain
approv
anim
experi
center
diseas
control
prevent
cdc
institut
anim
care
use
committe
iacuc
anim
work
perform
certifi
staff
associ
assess
accredit
laboratori
anim
care
aaalac
approv
biosafeti
level
vaccin
phase
challeng
phase
facil
cdc
produc
stock
singlecycl
virus
pseudotyp
vsv
g
glycoprotein
also
pseudotyp
niv
f
g
previous
describ
chattopadhyay
rose
vaccin
old
femal
syrian
golden
hamster
mesocricetu
auratu
charl
river
laboratori
wilmington
va
anesthet
isofluran
inocul
intramuscularli
right
quadricep
x
infecti
particl
either
anim
anim
anim
day
postvaccin
blood
collect
determin
serum
neutral
antibodi
titer
snt
previous
describ
chattopadhyay
rose
vaccin
hamster
along
addit
unvaccin
hamster
serv
unvaccin
control
transfer
lab
given
day
adjust
new
surround
day
postvaccin
challeng
day
hamster
inocul
via
intraperiton
rout
previous
describ
uniformli
lethal
challeng
dose
tcid
hamster
time
ld
niv
malaysia
strain
passag
time
vero
cell
chua
et
al
debuyssch
et
al
harcourt
et
al
rockx
et
al
anim
examin
score
daili
two
week
postchalleng
sign
clinic
ill
neurolog
diseas
respiratori
distress
weight
loss
weight
evalu
vaccin
group
began
day
postchalleng
anim
show
signific
weight
loss
initi
weight
challeng
day
alongsid
neurolog
respiratori
sign
human
euthan
anim
without
clinic
ill
day
postinfect
pi
continu
monitor
daili
weigh
day
interv
day
pi
surviv
anim
human
euthan
time
euthanasia
ml
blood
collect
cardiac
punctur
snt
determin
necropsi
perform
collect
lung
spleen
kidney
brain
tissu
tissu
either
inactiv
magmax
rna
lysi
buffer
life
technolog
carlsbad
ca
subsequ
rna
extract
realtim
rtpcr
previous
describ
lo
et
al
fix
formalin
histopatholog
immunohistochemistri
ihc
analysi
previous
describ
wong
et
al
day
postchalleng
unvaccin
control
hamster
either
die
euthan
due
develop
neurolog
sign
respiratori
distress
similarli
backbon
control
hamster
either
die
euthan
due
onset
ill
day
postchalleng
hamster
either
die
euthan
figur
contrast
hamster
vaccin
develop
clinic
ill
weight
loss
throughout
cours
infect
euthan
day
pi
day
postvaccin
figur
snt
niv
defin
reciproc
highest
serum
dilut
duplic
well
serum
sampl
show
complet
neutral
infecti
particl
prior
niv
challeng
hamster
vaccin
either
develop
respect
snt
hamster
vaccin
develop
detect
snt
figur
follow
niv
challeng
unvaccin
control
group
develop
low
level
neutral
antibodi
figur
even
serum
dilut
could
complet
neutral
particl
lack
anamnest
immun
respons
group
follow
niv
challeng
possibl
indic
steril
immun
respect
postchalleng
snt
time
euthanasia
remain
similar
prechalleng
level
compar
lower
percentag
neutral
higher
serum
dilut
figur
histopatholog
ihc
result
unvaccin
hamster
similar
observ
recent
studi
niv
pathogenesi
hamster
model
debuyssch
et
al
indic
bronchointerstiti
pneumonia
vascul
associ
viru
replic
figur
unvaccin
egfp
controlvaccin
group
detect
viral
rna
viral
antigen
tissu
sampl
group
except
brain
detect
viral
rna
viral
antigen
tabl
figur
data
shown
contrast
observ
patholog
could
neither
detect
presenc
viral
rna
antigen
tissu
collect
group
tabl
data
shown
summari
demonstr
singl
dose
singlecycl
vaccin
candid
express
either
niv
g
f
confer
complet
protect
lethal
niv
challeng
syrian
golden
hamster
anim
model
mark
contrast
previous
evalu
viral
vaccin
vector
express
niv
g
f
requir
multidos
primeboost
regimen
guillaum
et
al
weingartl
et
al
yoneda
et
al
except
adenovirusassoci
viru
aav
vector
requir
extrem
high
dose
vaccin
x
genom
particl
protect
ploquin
et
al
furthermor
compar
vector
express
niv
g
induc
higher
level
snt
day
postvaccin
vaccin
administ
anamnest
immun
respons
detect
addit
niv
challeng
dose
use
studi
least
time
greater
use
niv
vaccin
protect
studi
hamster
model
highlight
extrem
robust
protect
confer
niv
vaccin
replicationcompet
vsvbase
vector
express
appropri
foreign
antigen
shown
highli
effect
vaccin
number
viral
bacteri
pathogen
cobleigh
et
al
jone
et
al
kahn
et
al
kapadia
et
al
liao
et
al
palin
et
al
robert
et
al
robert
et
al
rose
et
al
regulatori
approv
vaccin
vector
human
slow
due
concern
regard
potenti
pathogenesi
hand
replicationdefici
vector
shown
induc
equival
even
greater
level
humor
cellmedi
immun
compar
correspond
replicationcompet
vector
particularli
vaccin
via
intramuscular
rout
kapadia
et
al
publicov
et
al
comparison
solubl
hev
g
subunit
vaccin
hevsg
current
anim
trial
vector
provid
advantag
first
foremost
advantag
singledos
requir
protect
second
advantag
lack
adjuv
requir
gener
robust
humor
cellmedi
thelper
type
immun
publicov
et
al
twodos
hevsg
vaccin
formul
requir
action
two
adjuv
allhydrogel
cpg
oligodeoxynucleotid
odn
bossart
et
al
order
gener
immun
respons
sinc
allhydrogel
alon
typic
induc
respons
appropri
viral
infect
coffman
et
al
steinhagen
et
al
weeratna
et
al
hevsg
vaccin
howev
hold
advantag
vector
vaccin
antigen
easili
produc
larg
scale
versu
product
infecti
particl
requir
multipl
plasmid
transfect
pallist
et
al
witko
et
al
result
report
studi
underscor
safeti
profil
robust
protect
confer
singl
dose
replicationdefici
singlecycl
vector
niv
futur
studi
establish
minimum
protect
dose
earli
protect
kinet
niv
vaccin
potenti
tool
prophylaxi
reduct
niv
diseas
sever
andor
mortal
singl
dose
vaccin
express
nipah
glycoprotein
protect
hamster
niv
vaccin
induc
high
level
serum
neutral
antibodi
one
dose
lack
detect
anamnest
immun
respons
indic
potenti
steril
immun
